Table I.
Baseline demographics of the 20 randomized patients.
| Characteristic | – |
|---|---|
| Sex, male, n (%) | 16 (80%) |
| Age, years, mean (SD) | 64.3 (11.9) |
| Race | – |
| Caucasian | 18 (90%) |
| Black | 2 (10%) |
| Other | 0 (0%) |
| Height, cm, mean (SD) | 171.4 (10.4) |
| Weight, kg | – |
| Mean (SD) | 83.6 (15.5) |
| Median (range) | 86 (55–106) |
| BMI, kg/m2 | – |
| Mean (SD) | 28.3 (3.9) |
| Median (range) | 28.6 (22.6–37.1) |
| Systolic BP, mmHg, mean (SD) | 134.8 (20.1) |
| Diastolic BP, mmHg, mean (SD) | 71.7 (11.7) |
| Pulse rate, bpm, mean (SD) | 59.2 (5.6) |
| Diagnosis | – |
| STEMI | 7 (35%) |
| NSTEMI | 13 (65%) |
| Unstable angina | 0 (0%) |
| Management of ACS | – |
| PCI | 16 (80%) |
| CABG | 0 (0%) |
| Conservative | 4 (20%) |
| Smoking status | - |
| Current | 2 (10%) |
| Past | 11 (55%) |
| Never | 7 (35%) |
| Diabetes mellitus | 3 (15%) |
| Hypertension | 11 (55%) |
| Hypercholesterolaemia | 9 (45%) |
| Time from ACS event to randomization, days, mean (SD) | 123.8 (82.8) |
| Concurrent medication | – |
| Beta-blocker | 17 (85%) |
| ACE inhibitor/ARB | 19 (95%) |
| Statin | 19 (95%) |
| Regular nitrate | 1 (5%) |
| Nicorandil | 1 (5%) |
| Proton pump inhibitor | 13 (65%) |
ACE, angiotensin converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; UA, unstable angina